H2020 European Research Council, Agence Nationale de la Recherche, Israel Science Foundation, Alex Grass Center for Drug Design and Synthesis Clinicians combat the drug resistances of some cancer types by using a combination of different drugs.
To make this approach more effective, chemists have designed a chemical conjugate that can simultaneously attack several cellular targets using different modes of action.
Such a single-drug therapy would increase the chances of killing all cancer cells, the authors state in the journal Angewandte Chemie.
The most frequently clinically applied chemotherapeutic drug is cisplatin, a metal complex based on the platinum(II) ion.
The drug’s mode of action is binding to the DNA in the tumour cells, where it distorts the DNA structure and ultimately triggers cell death.
Other chemicals facilitate the interaction of cisplatin with DNA, and they are often combined with cisplatin for chemotherapy.
The photodynamic therapy (PDT) approach, in contrast, relies on the activation of a metal complex by laser light.
A reactive form of oxygen is formed, which interferes with cell metabolism, triggering cell death.
“In clinical protocols, each drug is administered separately and may not reach the tumour at the same time or at a fixed ratio,” said Prof Gilles Gasser from the Paris Sciences et Lettres (PSL) University in Paris, France, who is one of the leading authors of the study.
His group, in collaboration with Prof Dan Gibson’s group from Hebrew University, Jerusalem, Israel, combined cisplatin, phenylbutyrate, which is a chemical enhancer for cisplatin, and a PDT drug, which is a metal complex based on ruthenium(II), into a single compound called Ru-Pt.
The idea was that the three drugs in conjunction could travel the bloodstream intact and enter their target tumour cells, which would reduce side effects and the need to adjust the dosages.
The scientists have designed the phototherapeutic Ru(II) half of Ru-Pt so that it can be excited with laser light in the deep red section of the wavelength spectrum, which penetrates deeply in the biological tissue.
The cisplatin and phenylbutyrate containing half of Ru-Pt was designed as a prodrug, which would be activated by cellular components inside the cell.
Both therapeutic components were attached to each other by a molecular spacer.
“The correct spacer length was critical to ensure that both drug compounds will not interfere with each other, but the molecule remains small, water-soluble, and able to travel across membranes,” Gasser said.
The researchers added Ru-Pt to some normal and cancer cell lines and found that Ru-Pt was significantly more efficient in killing cancer cells than the single compounds Ru(II) and Pt(IV).
The authors also reported that the irradiated samples had significantly higher tumour-killing rates, which means that the specific drug activation in tumour tissue is possible.
And finally, Ru-Pt had a ten times higher efficiency for drug-resistant cell lines than the single reagents.
These results demonstrate the high potential of multimodal drugs for developing more selective and effective drugs that have fewer side effects and allow for a simple handling for an effective cancer treatment.